Few topics in rheumatology have reshaped prescribing behaviour as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings.
EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where gout was high on the agenda. Current guidelines recommend lifelong urate-lowering therapy (ULT) in a treat-to-target (T2T) strategy to maintain remission, although there is some scope for discussing tapering or discontinuation if remission is achieved.
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed chimeric antigen receptor T (CAR-T) cell therapy may be an effective approach.
Chimeric antigen receptor (CAR) T‑cell therapy, long established in hematologic malignancies, is now emerging as a transformative approach in systemic lupus erythematosus (SLE), a disease historically managed with chronic immunosuppression.
We are in a transformative era in SLE which generates excitement to both physicians and people living with lupus. We now have four licensed biologics/targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis, and belimumab and anifrolumab for active non-renal SLE). Moreover, many other agents with different mode of action and administration are in late phase trials. This article previews some data being
A substantial portion of patients seen in rheumatology clinics are now older adults living with multimorbidity, polypharmacy, frailty, cognitive impairment, functional limitation, and competing health priorities. This week at EULAR 2026 in London, the EULAR Study Group on Geriatric Rheumatology holds its inaugural meeting. The launch marks an important step for a field that has been visible in clinical practice, but less visible in professional
Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.
Australia is facing a deepening rheumatology manpower crisis with direct parallels to the situation in the United States.
Patients with clinically suspect arthralgia (CSA), a common prequel to rheumatoid arthritis (RA), showed different patterns of symptoms and progression depending on whether they tested positive for anti-citrullinated protein antibodies (ACPA), researchers found.
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's supplemental Biologics License (sBLA) to include evidence in the guselkumab (Tremfya) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). Guselkumab is an IL-23 inhibitor indicated for use in psoriasis, psoriatic arthritis, ulcerative colitis and Crohn's disease.
Dr. Jack Cush reviews the news, journal articles and missed quiz questions.
A cross-sectional study of US adults with systemic lupus erythematosus (SLE) shows significantly increased prevalence of polypharmacy, related to age, disease outcomes and often, non-SLE common medications.
Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and individualized therapy.
Dr. Jack Cush reviews safety of biologics and novel agents.
